$1,000 follows their calls into $558
- Win rate
- 20%
- Streak
- —
- Best call
- No call read in the last 30 days
Track record building
- Peak #68
- 1 ranked close
Basket now
2 positions · Oct 19- VT2%
$1,000 follows their calls into $558
ESG_Biotech@ESG_BiotechI AM VOMIT. How could Claude be wronged? Wife is mad b/c my $LQDA short is downed big. She is say she is going to taked the lawyer boyfriend.
ESG_Biotech@ESG_BiotechI am decide after 100+ hour of due diligence (me and crack team of anals prompting the Claude), that $LQDA will getting pull from market and not be able to refile for 1+ year. This is because it is Hatch Waxman case and Judge Andrews is cucked the Norwood for Salix.
ESG_Biotech@ESG_BiotechI am decide after 100+ hour of due diligence (me and crack team of anals prompting the Claude), that $LQDA will getting pull from market and not be able to refile for 1+ year. This is because it is Hatch Waxman case and Judge Andrews is cucked the Norwood for Salix.
ESG_Biotech@ESG_BiotechDisaster. I, like many season I&I investor, am see dose response on malignancy table and am quickly selled the $ABVX. But now it look like no malignancy signal? This is mgmt fault for present maintenance data poorly. I will participating in class action.
ESG_Biotech@ESG_BiotechI am vomit. Selling out of $ABVX now. It is caused the NMSC. It will not selling. Drug is dead. Doctor won't prescribe.
ESG_Biotech@ESG_BiotechWow novel insight from Culper. $TARS is donate to patient assist fund, which is then help cover copay for random blepharitis patient who r often get the $TARS drug. This not good. I am believe this illegal and no other company r do this.
Culper@CulperResearchNEW: We are short Tarsus Pharmaceuticals $TARS, maker of XDEMVY, a $2,000 eyedrop for demodex blepharitis. We think XDEMVY rests on a TARS-funded Medicare copay scheme raising serious Anti-Kickback concerns, real TAM is a fraction of the hype, and $TARS whiffs on '26 FY numbers.

ESG_Biotech@ESG_BiotechNovel insight, wow. $LQDA is $AMRN 2.0.
Pharmdca@Pharmdca$LQDA reminds me about $AMRN story in hindsight. $LQDA is Yutrepia while $AMRN was Vascepa. In March 2020, Nevada judge invalidated VAscepa's patents and stock fell 67% in one day. Yesterday a Delaware judge found Yutrepia infringes UTHR patent and stock fell over 55%.